Breast Cancer

January 19, 2021 - The FDA’s Center for Devices and Radiological Health has granted premarket approval to diagnostic breast cancer imaging technology developed by Seno Medical Instruments to assist in the differentiation between benign and malignant breast lesions in patients.

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.

January 12, 2021 - Palbociclib in combination with endocrine therapy failed to result in a statistically significant improvement in progression-free survival over capecitabine in patients with hormone receptor–positive metastatic breast cancer who were resistant to aromatase inhibitors.

Martine J. Piccart discusses her journey into the breast cancer treatment space.

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.

January 5th, 2021 -The FDA has granted a fast track designation to the investigational antibody-drug conjugate ARX788 for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received 1 or more HER2-targeted regimens in the metastatic setting.

January 5, 2021 – The FDA has granted permission for a phase 1 study evaluating ON 123300, a first-in-class multikinase CDK4/6 inhibitor to proceed under the agent’s investigational new drug application.

Clinical risk continues to guide treatment decisions in early-stage HER2-positive breast cancer. The presence of brain metastases has become a driving force for treatment selection in the metastatic setting.

Sarah Sammons, MD, discusses the clinical significance of ESR1 mutations in HR-positive, HER2-negative breast cancer, how to determine the optimal timing to perform genetic sequencing for ESR1 mutations, and emerging agents, like lasofoxifene, that are poised to transform the paradigm for patients who harbor these mutations.

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

Ian E. Krop, MD, PhD, highlights the impact of the pivotal KATHERINE trial on the adjuvant treatment of patients with early-stage HER2-positive breast cancer and other recent advances that are moving the needle forward.

Joyce A. O’Shaughnessy, MD, highlights some of the most exciting updates in triple-negative breast cancer that emerged in 2020.

Neelima Vidula, MD, discusses the current and future utility of PARP inhibitors in triple-negative breast cancer, the promise of sacituzumab govitecan, and the need for germline genetic testing.

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Debra Patt, MD, highlights recent advancements and novel approaches in triple-negative breast cancer.

Debu Tripathy, MD, discusses strategies that can be used to overcome ESR1 mutations in estrogen receptor–positive breast cancer.

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.